Alisertib Completed Phase 2 Trials for Uterine Corpus Leiomyosarcoma / Recurrent Uterine Corpus Sarcoma Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01637961Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus